Jane Street’s Jasper Therapeutics JSPR Stock Holding History

Jane Street’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$42.8K	Buy	101,743 +80,328	+375%	+$60.1K	﹤0.01%	10993
2026 Q1	$18.8K	Buy	21,415 +11,051	+107%	+$15.3K	﹤0.01%	11203
2025 Q4	$19K	Buy	+10,364	New	+$20.8K	﹤0.01%	10742
2025 Q3	–	Sell	-132,905	Closed	-$738K	–	11307
2025 Q2	$738K	Buy	+132,905	New	+$654K	﹤0.01%	6198
2025 Q1	–	Sell	-10,852	Closed	-$232K	–	10043
2024 Q4	$232K	Sell	10,852 -2,502	-19%	-$52.1K	﹤0.01%	8164
2024 Q3	$251K	Buy	+13,354	New	+$266K	﹤0.01%	8315
2024 Q2	–	Sell	-41,894	Closed	-$1.23M	–	9802
2024 Q1	$1.23M	Buy	41,894 +40,773	+3,637%	+$724K	﹤0.01%	5031
2023 Q4	$8.84K	Buy	+1,121	New	+$7.52K	﹤0.01%	8976
2023 Q2	–	Sell	-21,101	Closed	-$382K	–	9153
2023 Q1	$382K	Buy	+21,101	New	+$390K	﹤0.01%	6788
2021 Q4	–	Sell	-2,603	Closed	-$267K	–	10468
2021 Q3	$267K	Buy	+2,603	New	+$266K	﹤0.01%	8408

Other funds holding JSPR

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

LPC

Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street's JSPR Position: Q2 2026 in Review

Jane Street increased its Jasper Therapeutics (JSPR) stake by 375% in Q2 2026, buying an estimated $60.1K and bringing the position to 101,743 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #10993.

Jane Street first reported a position in JSPR in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.23M in Q1 2024. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

Jane Street held 101,743 shares of Jasper Therapeutics worth $42.8K as of Q2 2026.
Jane Street bought 80,328 Jasper Therapeutics shares in Q2 2026, an estimated $60.1K.
Jasper Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #10993 holding.
Jane Street first reported a position in Jasper Therapeutics in Q3 2021 and has held it in 10 quarters since.
Jane Street's Jasper Therapeutics position peaked at $1.23M in Q1 2024.
45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.